These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37012321)

  • 1. Mutations linked to chemotherapy resistance in colorectal cancer.
    Fyfe I
    Nat Rev Gastroenterol Hepatol; 2023 May; 20(5):269. PubMed ID: 37012321
    [No Abstract]   [Full Text] [Related]  

  • 2. HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report.
    Boidot R; Chevrier S; Julie V; Ladoire S; Ghiringhelli F
    Int J Colorectal Dis; 2016 Jun; 31(6):1245-6. PubMed ID: 26561417
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer.
    Akhoundova D; Pietge H; Hussung S; Kiessling M; Britschgi C; Zoche M; Rechsteiner M; Weber A; Fritsch RM
    JCO Precis Oncol; 2021 Nov; 5():1082-1087. PubMed ID: 34994629
    [No Abstract]   [Full Text] [Related]  

  • 4. Precision Therapy in RAS Mutant Colorectal Cancer.
    Dienstmann R; Connor K; Byrne AT;
    Gastroenterology; 2020 Mar; 158(4):806-811. PubMed ID: 31972237
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
    De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
    Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
    Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
    Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal Cancer.
    Mondaca S; Walch H; Nandakumar S; Chatila WK; Schultz N; Yaeger R
    Gastroenterology; 2020 Nov; 159(5):1975-1978.e4. PubMed ID: 32730818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
    Chuang J; Wang C; Guo Y; Valenzuela V; Wu J; Fakih M
    Clin Colorectal Cancer; 2021 Mar; 20(1):72-78. PubMed ID: 33436306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are RAS mutations predictive markers of resistance to standard chemotherapy?
    Loriot Y; Mordant P; Deutsch E; Olaussen KA; Soria JC
    Nat Rev Clin Oncol; 2009 Sep; 6(9):528-34. PubMed ID: 19597509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Will PICCOLO affect metastatic colorectal cancer therapy?
    Eng C
    Lancet Oncol; 2013 Jul; 14(8):679-80. PubMed ID: 23725852
    [No Abstract]   [Full Text] [Related]  

  • 11. COMMENTARY. Pre-emptive Nutrition: Refining the Targets of Drugs Targeted to Colorectal Cancer.
    Ferguson LR; Denny WA
    Curr Cancer Drug Targets; 2015; 15(3):173-5. PubMed ID: 25986644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for colorectal cancer resistance to EGF receptor antibodies and new trends.
    Katsios C; Ziogas DE; Roukos DH; Baltogiannis G
    Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):5-8. PubMed ID: 23265143
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.
    Chen Q; Xia HW; Ge XJ; Zhang YC; Tang QL; Bi F
    Asian Pac J Cancer Prev; 2013; 14(12):7421-6. PubMed ID: 24460313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
    Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan and mismatch repair deficiency.
    Power DG; Feilchenfeldt J
    Ann Oncol; 2010 Feb; 21(2):432-433. PubMed ID: 19940003
    [No Abstract]   [Full Text] [Related]  

  • 16. Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer.
    Sameen S; Barbuti R; Milazzo P; Cerone A; Del Re M; Danesi R
    J Theor Biol; 2016 Jan; 389():263-73. PubMed ID: 26551156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating
    Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
    World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.
    Huijberts SCFA; Boelens MC; Bernards R; Opdam FL
    Br J Cancer; 2021 Jan; 124(1):176-182. PubMed ID: 33204026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer.
    Lampropoulou DI; Aravantinos G; Katifelis H; Lazaris F; Laschos K; Theodosopoulos T; Papadimitriou C; Gazouli M
    Cancer Biomark; 2019; 25(2):213-221. PubMed ID: 31045514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan.
    Saeki H; Emi Y; Kumashiro R; Otsu H; Kawano H; Ando K; Ida S; Kimura Y; Tokunaga E; Oki E; Morita M; Shimokawa M; Maehara Y
    Surg Today; 2014 Aug; 44(8):1457-64. PubMed ID: 24013837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.